Shamburg News · 8-K filed Oct 30, 2026, 8:00 AM EDT

NextCure Terminates Chief Medical Officer Udayan Guha Ahead of Avere Merger

NXTC · NextCure, Inc.

  • Leadership change
  • Material agreement
  • Materiality: high

On October 26, 2026, NextCure, Inc. determined that the employment of Chief Medical Officer Dr. Udayan Guha will be terminated effective October 31, 2026, in contemplation of its pending merger with Avere Therapeutics, Inc. Dr. Guha entered into a severance agreement and release providing severance consistent with a termination without cause under his existing employment agreement, with additional change-in-control severance conditioned on the merger closing.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 5.02, accession 0001104659-26-120405.

Written from the filing by Shamburg Markets. Figures are as reported by the company.